IVD firms now must pay to get new GMDN terms in Aus
This article was originally published in Clinica
Australia's Therapeutic Goods Administration is no longer providing assistance to in vitro diagnostic manufacturers and sponsors relating to the development of new Global Medical Device Nomenclature (GMDN) terms.
You may also be interested in...
Swissmedic will scale back its review procedure for certain anti-infectives if the indications for which approval is being sought are identical to those approved in the EU or the US.
Based on the operational experience gained using the new international standard for reporting suspected adverse reactions in EudraVigilance, the EU has decided to set a date for its mandatory use.
The UK’s Health Research Authority has agreed in principle to implement a new policy that aims to drive a lasting change in clinical trial transparency. Not everyone is convinced.